Nasdaq:US$16.50 (-0.18) | HKEX:HK$26.55 (-0.10) | AIM:£2.74 (+0.06)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
APPROVED & MARKETED
PRODUCT IN THE U.S.
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
5,000
PERSONNEL ACROSS
THE GROUP

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


Annual General Meeting 2024 2024-05-10
Guotai Junan Healthcare Globalization Forum, Shanghai 2024-03-19 - 2024-03-19
Soochow Securities 4th Innovative Drug Forum & BD Conference, Suzhou 2024-03-12 - 2024-03-12